X0306 4 2017-10-13 1 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001307632 Hawkins Richard J 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 1 0 0 0 Common Stock 2017-10-13 4 D 0 24363 11.18 D 0 D Non-Qualified Stock Option (right to buy) 6.04 2017-10-13 4 D 0 30000 5.14 D 2021-06-30 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 6.78 2017-10-13 4 D 0 30000 4.40 D 2022-06-07 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 5.13 2017-10-13 4 D 0 30000 6.05 D 2023-06-27 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 5.10 2017-10-13 4 D 0 30000 6.08 D 2024-06-12 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 9.15 2017-10-13 4 D 0 30000 2.03 D 2025-06-11 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 10.90 2017-10-13 4 D 0 30000 0.28 D 2027-06-08 Common Stock 30000 0 D Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012. The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger. /s/ Friedhelm Blobel, Attorney-in-Fact for: Richard J. Hawkins 2017-10-16